Collaboration as the best medicine by Srai, Jagjit Singh & Badman, Clive
Srai, Jagjit Singh and Badman, Clive (2019) Collaboration as the best 
medicine. Chimica Oggi/Chemistry Today, 37 (1). pp. 10-13. ISSN 0392-
839X , 
This version is available at https://strathprints.strath.ac.uk/67689/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
Jagjit Singh Srai1, Clive Badman2 
1. Centre for International Manufacturing, Institute for Manufacturing, 
Department of Engineering, University of Cambridge, United Kingdom 
2. Business Engagement Group, University of Strathclyde, United Kingdom 
 
 
Collaboration as the Best Medicine 
 
abstract 
Collaboration can be pivotal in making change happen. So how can new collaborative models be 
forged in areas where such relationships are not well established, but where change is required? 
 
In UK medicines manufacturing, there is an opportunity and a pressing need for progressive change. 
But there are also plenty of challenges and obstacles, particularly in a highly competitive and tightly 
regulated sector. A bold step forward has been taken through a collaborative £23m four-year project, 
ReMediES, involving 22 industry partners and 2 leading UK Universities. 
 
Dr Jag Srai and Professor Clive Badman, co-Directors of Project ReMediES discuss how the project has 
forged a model for change through collaboration. 
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Medicines manufacturing is an important part of the UK economy, employing 40,000 people and 
generating $33 billion in exports. In many ways, it is productive, strong and successful. However, there is 
potential for making significant improvements across the medicines manufacturing supply chain.  
 
dŚĞƉŚĂƌŵĂĐĞƵƚŝĐĂůŝŶĚƵƐƚƌǇ ?Ɛ size, scale and complexity, alongside its highly-competitive character, 
have made change difficult. There is an entrenched pattern of long product development cycles with 
high attrition rates, leading to development costs of around $2.6 billion per product. Clinical trials often 
take place many months after the trial drugs have been manufactured, resulting in significant stock 
write-offs of 50% or more. The commercial supply chain has become cumbersome and inventory-heavy. 
Furthermore, the sector is highly regulated, which instils caution. 
 
While this status quo may sound problematic and somewhat bleak, in fact it has provided a much-
needed stimulus for industry players to seek improvements, and a motivation to reach over those high 
competitive walls and collaborate for mutual benefit. 
 
 
REMEDIES FOR CHANGE 
 
Within our advanced manufacturing research programmes we have been working with major players in 
the pharmaceutical industry for several years on the possibilities that new production and digital 
technologies can offer to both industry and patients. These can support more responsive inventory-light 
supply chains, able to deliver medicines more targeted to specific patient groups or even personalised to 
individuals, with the potential to revolutionise healthcare delivery. However this transformation is too 
much for a single company, even a multinational, to achieve in isolation. So as a step in the right 
direction, we developed a vision for a large pre-competitive collaborative project to drive change, with 
the active participation of the regulator. 
 
In 2014, the ReMediES (Reconfiguring Medicines End-to-End Supply) project was launched, bringing 
together 22 industrial partners including global pharmaceutical companies GlaxoSmithKline and 
AstraZeneca, as well as major contract manufacturing organisations, equipment manufacturers, 
international logistics specialists and a global pharmacy. The Universities of Cambridge and Strathclyde 
provided expertise in supply chain and pharmaceutical product and process engineering. 
 
This broad partnership addressed some of the key challenges facing small molecule medicines 
manufacturing, with eight workstreams focusing on different aspects of clinical and commercial supply 
chains. 
 
From a research perspective, across the ReMediES workstreams, we have attempted to tackle some 
ambitious questions. Could we run our clinical trial production more efficiently  ‘ŽŶ-ĚĞŵĂŶĚ ? ?reducing 
waste, inventory and lead-times? Could we adopt advanced technologies to make both our primary and 
secondary manufacturing processes right first time, more environmentally sustainable and capable of 
responding to changing demand? Could we apply science to create more soluble medicines? Could we 
package medicines in ways that will reduce wastage and help with patient compliance? And could we 
get better at delivering drugs to the people who need them, when they need them? 
 
Over its four-year timescale, the ReMediES partners worked to tackle these fundamental, cross-sector, 
cross-functional challenges. The partners were able to take fundamental and applied research through 
to prototype or commercialisation. 
 
From an industry perspective, we had observed that many of the firms have experimented with some of 
the technologies we are talking about in ReMediES but have not had the scale and the expertise that the 
ReMediES consortium offers to take things forward. 
 
 
HIGHLIGHTS OF THE PROJECT 
 
So what were the positive outputs from this collaborative approach? As the project reaches the end of 
its funding, partners have been reflecting and reporting on some of its key achievements, including in 
ƚŚĞĨŽůůŽǁŝŶŐĂƌĞĂƐ ? 
 
 
 
Clinical Supply Chains  ?  ?:ƵƐƚŝŶdŝŵĞ ? 
Clinical trials are a critical part of pharmaceutical R&D, but are increasingly complex to manage, often 
involving thousands of patients at hundreds of sites in different countries. At the same time, the sector 
wants to bring new medicines to market more quickly and more cheaply. 
 
In the current system, it typically costs in excess of £75 million to run a clinical trial for a new drug; a 
significant cost considering only 25% of drugs trialed make it into commercial production.  
 
Because the sector is still reliant on high-volume production techniques it has to manufacture a trial 
drug in large quantities, often before the patients have been recruited, sometimes without confirmation 
that the trial is going ahead. Clinical teams have to decide doses and quantities of a trial drug to be 
manufactured 12 to 18 months before they expect to use it. As a result, more drugs are made than are 
needed to cover contingencies.  
 
The process is also not sufficiently agile to respond to the changing circumstances inherent in any trial. 
For example, early results might suggest altering dosing or randomization strategies. 
 
The ReMediES clinical trials workstream looked at how this could be improved, with the ambitious aim 
to cut supply time from 4-6 months to less than a week, and develop the ability to be agile to changing 
trial needs. 
 
As commented by the Project Lead for Clinical Trial Supply Chains, Andrew Dwyer from GSK, 
 “tĞƉƌŽƚŽƚǇƉĞĚ ĂŶĞǁ ‘:ƵƐƚ-in-dŝŵĞ ?ĐůŝŶŝĐĂůƉŚĂƌŵĂĐǇƚŚĂƚ can provide drugs to support 
complex drug trials, reducing costs, increasing responsiveness and enabling a more flexible and 
exploratory approach to clinical research. 
 
 “dŚĞŵŽĚĞůůŝŶŐŽĨƐƚŽĐŬŝŵƉůŝĐĂƚŝŽŶƐĨŽƌĂŵĂĚĞ-to-order facility has demonstrated that the 
potential benefit of an automated clinical pharmacy could be savings of tens of millions of 
pounds per ǇĞĂƌƉĞƌĐŽŵƉĂŶǇ ? ? 
 
Primary Manufacturing  ? ĨƌŽŵďĂƚĐŚƚŽ ?ĐŽŶƚŝŶƵŽƵƐƉƌŽĐĞƐƐŝŶŐ ? 
The challenges at the primary manufacturing stage are similar to those facing the clinical supply chain: a 
reliance on the overproduction of stock to mitigate a lack of agility in the supply chain, creating a high 
level of wastage. The sheer scale of batch manufacturing means that mistakes are expensive. If 
something goes wrong in a 10,000 litre vessel, the waste of energy and materials is significant. In 
continuous manufacturing, on the other hand, the process is constantly monitored and adjusted to 
ensure quality. 
 
Through a number of related projects, ReMediES has made significant progress in developing new 
chemistries and processes that support the move from batch to continuous manufacturing, shrinking 
factory scale, increasing speed and reducing cost.  
 
It has resulted in: 
 ? New equipment for continuous processing with immediate commercial applications that support 
right-first time manufacturing, yield improvements and inventory reduction. 
 ? The development of a new GMP supercritical fluid manufacturing facility in the UK. 
 ? Significant advances in biocatalysis and the use of enzymes in flow. 
 
 
BlackTrace is one of the continuous manufacturing technology platforms developed within Remedies. It 
provides a complete continuous processing scale-up including reaction, separation and particle 
formation, and will be commercially available from 2019. 
 
Secondary Manufacturing 
A major three-part project in secondary manufacturing has piloted new equipment for capabilities that 
enable shorter production cycles and volume flexibility.  
 
Liz Meehan, responsible for Pharmaceutical Technology and Development at AstraZeneca, and project 
leader for the Secondary Processing workstream in ReMediES, comments: 
 “ŵŽƌĞĨůĞǆŝďůĞĂŶĚĂŐŝůĞmedicines supply chain will be enabled by wider implementation of 
advanced (continuous or additive) manufacturing processes for both drug substance and drug 
producƚ ? ? 
 
The ReMediES project included user trials and case studies for some strategic technology platforms 
including continuous drug substance isolation, continuous direct compression, hot melt extrusion and 
3D printing.  As Liz Meehan explains:  
 “ǇƚĂŬŝŶŐĂ multidisciplinary approach, ReMediES has shown how these advanced 
manufacturing processes can be deployed and accelerated to meet the challenges of future 
ĐůŝŶŝĐĂůĂŶĚĐŽŵŵĞƌĐŝĂůƐƵƉƉůǇĐŚĂŝŶƐ ? ? 
 
Substantial reductions in the cost of production will result, estimated in one company alone at £10m per 
year once fully implemented. 
 
Smarter Packaging 
The ReMediES packaging workstream, in which AstraZeneca and GSK have collaborated closely, looked 
at using new materials and processing techniques to improve blister pack moisture barrier properties 
whilst at the same time reducing their size leading to significant cost-savings and reductions in 
environmental impact. 
 
This production process is going to full trial suggesting a 10 fold improvement in moisture barrier 
compared with other similar cost materials. For one company alone it could mean, based on an 
application on a leading product: 
 ? A reduction in CO2 emissions of 700 tonnes annually. 
 ? Savings of around £380k for materials and £1.5million on distribution. 
 ? A material productivity increase of 25%. 
 
The ReMediES team, led by Centre for Process Innovation (CPI) also developed smart labels for use on 
medicines packaging using printed electronics which enable product tracking, monitoring and could be 
used to support patient engagement. Successful demonstration is leading to commercialisation 
opportunities that are being pursued with leading packaging manufacturers.  
 
Digitalisation of Commercial Supply Chains 
Several projects have underpinned the development of future supply chain models led by the team at 
IfM Cambridge.  
  
Drawing data from 138 companies and 34 research organisations an asset library for use across the 
ŝŶĚƵƐƚƌǇǁĂƐĚĞǀĞůŽƉĞĚŝŶƚŚĞĨŽƌŵŽĨĂ ‘ĐĂƉĂďŝůŝƚǇŵĂƚƌŝǆ ?ƐĞƚƚŝŶŐŽƵƚǁŚĂƚĂƐƐĞƚĐĂƉĂďŝůŝƚŝĞƐexist 
across extended supply chain. This was then extended using extensive data-mining of commercial 
databases, to identify collaborative relationships in key capability areas. An interactive digital platform 
tool was created for use by Remedies partners to interrogate the current collaborative network across 
the UK pharmaceutical landscape for specific asset capabilities, and to foster future collaboration.  
 
A number of projects were conducted in the use of specific digital technologies across the end-to-end 
supply chain. These include an electronic patient-information leaflet, to co-exist or potentially replacing 
the paper version used in medicine packs, developed in consultation with the regulator, with a 
prototype mobile phone app providing patients electronic access. The hope is that such innovations can 
increase patient compliance and reduce waste.  
 
An end-to-end supply network design, analysis and modelling platform has also been developed to help 
manufacturers understand the opportunities available to reduce inventory and increase speed-to-
market. The multi-layer modelling platform allows organisations to evaluate new production processes, 
how these might influence production location and scale, inventory requirements of segmented product 
portfolios and market service levels.  As Dr Srai commented on the work in his Centre being led by Dr 
Ettore Settanni,  ‘We can slice and dice a range of data to observe the interplay between cost, service and 
environmental resource efficiency in an integrated way: from a unit operations production processes 
perspective, a manufacturing footprint analysis and the final distribution of medicines to patients - 
ƌĂƚŚĞƌƚŚĂŶƚŚĞĨƵŶĐƚŝŽŶĂů ?ƐŝůŽƐ ?ŝŶǁŚŝĐŚŶĞǁƚĞĐŚŶŽůŽŐŝĞƐĂƌĞŽĨƚĞŶĂƐsessed ? 
 
The workstream also ĂŶĂůǇƐĞĚ ‘ůĂƐƚ-ŵŝůĞ ?ůŽŐŝƐƚŝĐƐ ?ǁŝƚŚŐůŽďĂůƉŚĂƌŵĂĐǇůůŝĂŶĐĞ,ĞĂůƚŚĐĂƌĞ ?ĂŶĚůŝĨĞ
sciences division of the logistics specialist, DHL, as part of the ReMediES project. Adopting approaches 
used by the IfM researchers in FMCG and retail distribution logistics, the team modelled direct supply to 
patients to evaluate feasibility in terms of cost and service levels. 
 
 
Visualisation of numbers of prescriptions being processed by pharmacists in selected postcodes over the 
course of a month 
 
It has not all been hard work and no play  W the team have for example used gamification to develop a 
mobile app helping industry experts and multiple supply chain stakeholders within the Remedies 
program evaluate otherwise complex risk interdependencies across the extended supply chain. This 
work links well with a broader disruption risk assessment tool available from SME Remedies partner 
Intersys (http://intersys.co.uk), now marketed commercially. 
 
 
WHAT NEXT? 
 
The work of ReMediES will continue through the new £56 million Medicines Manufacturing Research 
Centre (MMIC), located in Glasgow, which is jointly funded by Innovate UK, Scottish Enterprise, GSK and 
AstraZeneca.  
 
MMIC is designed to help both start-ups and multinational pharmaceutical companies adopt novel 
processes and technologies and customise them to integrate with their own manufacturing processes. 
Just-in-ƚŝŵĞĐůŝŶŝĐĂůƉŚĂƌŵĂĐǇĂŶĚĐŽŶƚŝŶƵŽƵƐĚŝƌĞĐƚĐŽŵƉƌĞƐƐŝŽŶĂƌĞDD/ ?ƐĨŝƌƐƚŐƌĂŶĚĐŚĂůůĞŶŐĞƐ ? 
ƚĂŬŝŶŐĨŽƌǁĂƌĚƚŚĞǁŽƌŬŽĨƚǁŽŽĨZĞDĞĚŝ^ ?ƐĐŽƌĞƉƌŽũĞĐƚƐ ? 
 
 
FORGING A MODEL FOR COLLABORATION 
 
Whilst new technologies are offering major opportunities to patients, healthcare providers and 
manufacturers, they require new collaborative platforms to address the complex technical and 
ƌĞŐƵůĂƚŽƌǇĐŚĂůůĞŶŐĞƐƚŚĂƚĂƌĞŝŶǀŽůǀĞĚ ?/ƚ ?ƐƚŽŽďŝŐƚŽĚŽĂůŽŶĞ ? 
 
However, the concept of pre-competitive collaboration is relatively new in the medicines manufacturing 
arena, and many companies are concerned about becoming engaged from a cost and IP perspective. 
ReMediES addresses this concern in part by providing an exemplar collaboration model where 
innovations emerging from fundamental and applied research can be taken to prototype or 
commercialisation. The platform has enabled multi-stakeholder perspectives to be considered drawing 
in expertise from technology providers, regulators, academia and industry. Individual firms have been 
able to leverage their resources, upwards of 50% on direct activity, and by greater than 300% at a 
programme level.  
 
Dr Will Barton, Chairman of the Advisory Board of the EPSRC Centre of Innovative Manufacturing in 
Additive Manufacturing, was the independent advisor to the ReMediES Project. He comments: 
 
 “ReMediES was one of the early examples of the Pharma industry working together in 
collaborative R&D, something it didn't have a record of doing before. The project, even in its 
early stages, started to show the value of such collaboration, that you don't have to share your 
crown jewels and that there are a lot of non-competitive or pre-competitive areas where 
companies can work together if they choose to, which can benefit the whole UK pharmaceutical 
industry. 
 
 “ReMediES was a well-run project that will deliver some early wins for the SMEs and 
longer-term impacts across the board. It was really exciting seeing teams deliver great 
results. Things happened that nobody would have believed possible at the start. ? 
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